Compare AES Corp (AES) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AES Corp vs Summit Therapeutics Inc — how do they compare? AES Corp trades at $14.73 (market cap $10.49B), while Summit Therapeutics Inc trades at $15.05 (market cap $12.06B). The key difference: AES Corp and Summit Therapeutics Inc are close in size by market cap, and AES Corp pays a 4.79% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AES | SMMT | |
|---|---|---|
Market Cap | $10.49B | $12.06B |
Sector | Utilities | Health |
52-Week High | $17.28 | $26.98 |
52-Week Low | $12.51 | $12.55 |
Enterprise Value | $40.75B | $11.39B |
Dividend Yield | 4.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AES trades at $14.725, down 0.03% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 14.34% net income margin and a low P/E of 5.51. Recent news highlights a pending $33.4 billion acquisition by a consortium led by Global Infrastructure Partners and EQT, approved by stockholders in June 2026, alongside a quarterly dividend of $0.17595 per share.
The stock offers a high dividend yield and appears undervalued based on earnings, but faces risks from the acquisition's regulatory scrutiny and a recent earnings miss. Upside is capped near the $15 buyout price if the deal closes, while downside exists if approvals fail. Analyst sentiment is mixed with no sell ratings but a majority on hold.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
